While some studies demonstrated a decreased risk for overall cancer associated with ARBs use and this mainly due to blocking the AT1R effect,[15] others showed its use increased the incidence of some neoplasms (carcinogenic compounds of some ARBs: N-nitrosodimethylamine in valsartan in 2018 followed by N-nitrosodiethylamine in valsartan, losartan and irbesartan, and third nitrosamine product later on,[16] and also the unopposed action of the AT2R, etc.).[17] Moreover, a cohort study showed a neutral effect of ARBs use on lung and CRC.[18]. Here, AGTR1 is linked to cancer.